Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG (OCS) generates a steady flow of news related to its late-stage biopharmaceutical pipeline in ophthalmology and neuro-ophthalmology. Company announcements highlight clinical trial milestones, regulatory designations, capital markets activity, and scientific presentations that are relevant for investors and observers tracking developments in optic neuropathies and retinal disease.
Recent news releases describe the advancement of Privosegtor, a peptoid small-molecule neuroprotective candidate, into the PIONEER registrational program for optic neuritis and non-arteritic anterior ischemic optic neuropathy. Oculis has reported positive Phase 2 ACUITY data in acute optic neuritis and disclosed that Privosegtor has received Breakthrough Therapy designation from the U.S. FDA and Orphan Drug designation from the FDA and EMA. Updates often cover trial design, endpoints such as low-contrast visual acuity, and planned global enrollment.
News coverage also follows OCS-01 eye drops in Phase 3 DIAMOND studies for diabetic macular edema, including the use of the company’s OPTIREACH technology to deliver dexamethasone topically to the retina. In addition, Oculis issues releases on Licaminlimab for dry eye disease, participation in major medical meetings such as the J.P. Morgan Healthcare Conference and ophthalmology congresses, and insider transaction notifications related to restricted stock unit vesting and director share purchases.
For readers monitoring OCS, this news feed provides company-sourced updates on clinical progress, regulatory interactions, financing transactions disclosed in Form 6-K filings, and scientific data presentations. It can be a useful reference for following how Oculis advances its investigational therapies for optic neuritis, NAION, diabetic macular edema, and dry eye disease over time.
Oculis (Nasdaq: OCS) announced the U.S. FDA granted Breakthrough Therapy Designation to Privosegtor for treatment of optic neuritis on January 6, 2026. The designation is supported by Phase 2 ACUITY data showing an average +18‑letter gain in Low Contrast Visual Acuity (LCVA) at month 3 versus IV steroid alone, plus anatomical preservation and reduced neurofilament release. Oculis launched the registrational PIONEER program after a 2025 FDA meeting; PIONEER includes three pivotal trials and PIONEER‑1 in optic neuritis was initiated in Q4 2025 with global site activation and enrollment expected to begin shortly. The company cites a U.S. market opportunity of $7 billion for key optic neuropathies.
Oculis (OCS) announced a notification relating to the vesting and settlement of restricted stock units (RSUs) previously granted to a director. The notice names Riad Sherif and is dated January 5, 2026; an attachment titled "Notification of managers' transaction - Riad Sherif - January 2026 RSU vest" is referenced.
The announcement reports the administrative event only and does not disclose amounts, prices, or additional financial details.
Oculis (OCS) published notifications dated Dec 9, 2025 reporting the vesting and settlement of restricted stock units (RSUs) previously granted to company directors. The notifications name four directors: Anthony Rosenberg, Christina Ackermann, Arshad Khanani, and Robert Warner, and indicate these RSUs vested/settled in December 2025.
These are routine managers' transaction disclosures concerning executive/director compensation events; no financial amounts or additional terms were included in the text provided.
Oculis (Nasdaq: OCS) will highlight its late-stage ophthalmology pipeline at Eyecelerator and the AAO Annual Meeting in Orlando on October 16-20, 2025.
Key updates include the acceleration of Privosegtor into registrational trials after a positive FDA meeting, topline readouts from the Phase 3 DIAMOND program for OCS-01 in diabetic macular edema expected in Q2 2026, and the planned start of the genotype-based PREDICT-1 registrational trial for Licaminlimab anticipated in Q4 2025. Presenters include CEO Riad Sherif, MD and retina advisor Arshad M. Khanani, MD.
Oculis (OCS) announced a notification concerning the vesting and settlement of restricted stock units (RSUs) previously granted to a director.
The notification identifies Arshad Khanani and records an RSU vest dated 29 November 2025.
Oculis (OTC:OCS) announced a notification of a managers' transaction relating to the vesting and settlement of restricted stock units (RSUs) previously granted to a company director.
The notification names Arshad Khanani and cites an RSU vesting event dated 25 November 2025. No financial amounts or additional transactions were disclosed.
Oculis (Nasdaq: OCS) announced that a positive FDA meeting enables a registrational development program for Privosegtor in acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION).
The company will launch the PIONEER program with three pivotal trials: PIONEER-1 (AON, expected Q4 2025), PIONEER-2 (AON, 1H 2026) and PIONEER-3 (NAION, mid-2026). Primary endpoint: low-contrast visual acuity at 3 months. Trials will mirror Phase 2 ACUITY dosing/enrollment. Oculis reported ≈$182 million cash and short-term investments as of Sept 30, 2025, with a cash runway into 2H 2027. Management will host an analyst call today at 8:30 AM ET.
Oculis (SIX:OCS) announced a notification dated November 18, 2025 reporting a purchase of ordinary shares by a member of the company's Board of Directors.
The notice references an attachment named notification-of-managers-transaction-lionel-carnot-november-2025, indicating the transaction involves director Lionel Carnot.
Oculis (Nasdaq: OCS) announced positive Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis, to be presented at ECTRIMS 2025 on September 24, 2025, 08:30 CET by Céline Louapre, M.D., Ph.D.
Topline findings reported a clinically meaningful improvement of 18 letters at 3 months, preservation of retinal ganglion cells, and a favorable safety profile. Management said the data support Privosegtor’s neuroprotective potential and plans to advance the candidate into further studies, including a program targeting MS relapses.
Oculis (Nasdaq: OCS) reported Q3 2025 results and outlined clinical and financing milestones. The company held $182.2M in cash, cash equivalents and short-term investments as of Sept 30, 2025 and completed a subsequent $110M financing that management says brings cash close to $300M, extending runway into 2029.
Key program updates: Privosegtor enters the PIONEER pivotal program (three trials: PIONEER-1 Q4 2025, PIONEER-2 H1 2026, PIONEER-3 mid-2026) for AON and NAION; OCS-01 DIAMOND Phase 3 trials are fully enrolled (>800 patients) with topline readouts expected Q2 2026 and NDA planned 2H 2026; Licaminlimab registrational genotype-based DED trial expected to start Q4 2025.